Yes, histone acetylation is a post-translational modification. It occurs after histone proteins have been synthesized, when enzymes add small chemical tags (acetyl groups) to specific amino acids on the histone’s tail. This modification changes how tightly DNA wraps around histones, directly influencing which genes get turned on or off.
How Histone Acetylation Works
Histones are spool-like proteins that DNA wraps around inside every cell. The tails of these proteins stick out and carry a positive electrical charge, which attracts the negatively charged DNA and keeps it wound tightly. When an acetyl group is added to a lysine residue on a histone tail, it neutralizes that positive charge. The grip between the histone and DNA loosens, the DNA unwinds slightly, and the genes in that region become accessible to the cell’s machinery for reading and copying them.
The enzymes responsible for adding acetyl groups are called histone acetyltransferases, or HATs. They pull an acetyl group from a donor molecule called acetyl-CoA and attach it to specific lysine residues on the histone tail. This is what makes it a post-translational modification: the histone protein is already fully built, and the acetyl group is added afterward as a chemical edit that changes the protein’s behavior without altering its underlying sequence.
Where Acetylation Happens on Histones
Not every spot on a histone gets acetylated. The modification targets specific lysine positions, and different positions carry different biological meanings. On histone H3, the five most commonly acetylated lysines sit at positions 9, 14, 18, 23, and 27 along the tail. Histone H4 is frequently acetylated at lysines 5 and 12, with less modification at lysines 8 and 16.
Acetylation isn’t limited to the flexible tails, either. Lysine 56 on histone H3 sits within the core structure of the protein, closer to where DNA actually contacts the histone. Histone H4 can also be acetylated at lysine 91 in its core domain. These core modifications are rarer but can have distinct effects on DNA packaging and repair.
The Process Is Reversible
One of the defining features of histone acetylation is that it can be undone. A second family of enzymes, histone deacetylases (HDACs), strips acetyl groups off lysine residues. When the acetyl group is removed, the positive charge on the lysine returns, the histone grabs DNA more tightly, and the chromatin compacts. Genes in that region become harder for the cell to read, effectively silencing them.
Mammals have 18 known HDACs, grouped into four classes. Classes I, II, and IV rely on zinc to function, while class III (the sirtuins) requires a different cofactor derived from vitamin B3. Classes I and II handle most of the heavy lifting when it comes to removing acetyl marks from histone tails. This back-and-forth between HATs adding acetyl groups and HDACs removing them is one of the major systems cells use to control gene expression, and it’s a core part of what scientists call epigenetic regulation.
How Cells Read Acetyl Marks
Adding or removing an acetyl group changes the physical structure of chromatin, but the cell also has specialized “reader” proteins that recognize these marks and act on them. The most important readers contain a structure called a bromodomain, a pocket-shaped region that physically grips acetylated lysine residues.
Bromodomain proteins generally do one of three things. Some are part of HAT complexes themselves: they recognize an acetylated histone, anchor the complex to it, and then acetylate neighboring histones, spreading the open-chromatin signal along the DNA. Others belong to chromatin remodeling complexes that physically reposition histones to expose gene promoters. A third group, the BET proteins, recruit general transcription factors that directly kick-start gene copying. For instance, one BET protein (Bdf1) binds acetylated histone H4 and recruits a transcription factor called TFIID, which is essential for initiating gene expression at many genes.
This layered system (writers, erasers, and readers) means histone acetylation doesn’t just passively loosen DNA. It actively recruits the molecular machinery needed to turn genes on.
Metabolism Controls the Supply of Acetyl Groups
Because HATs need acetyl-CoA as their raw material, the rate of histone acetylation is tied to cellular metabolism. Acetyl-CoA sits at a crossroads of energy production: it’s generated from glucose, fatty acids, and amino acids. When cells have plenty of fuel, acetyl-CoA levels rise, more acetyl groups are available for histones, and gene activity tends to increase. When fuel is scarce, as during fasting or calorie restriction, acetyl-CoA levels drop, histone acetylation decreases, and the cell shifts toward maintenance and recycling programs like autophagy.
The enzyme ACLY is responsible for converting citrate (from the cell’s energy cycle) into cytoplasmic acetyl-CoA, and it drives the vast majority of histone acetylation in many cell types. In brain cells, particularly in the hippocampus, a different enzyme called ACSS2 localizes directly to the nucleus and converts acetate into acetyl-CoA right where histones are. This means the brain’s histone acetylation patterns can respond to acetate availability independently of the rest of the body’s metabolic state. In animal studies, acetate supplementation increased acetylation at specific marks on histones H3 and H4 in the brain but not in the liver.
Age-related declines in acetyl-CoA production, particularly through reduced activity of the enzyme complex that feeds acetyl groups into the energy cycle, may contribute to decreased histone acetylation in the aging brain.
Why It Matters in Medicine
Because histone acetylation controls which genes are active, disruptions to this system play a role in diseases where gene expression goes wrong, particularly cancer. Tumor cells often have abnormal HDAC activity that silences genes meant to suppress growth. Blocking HDACs with drugs can reactivate those silenced genes and slow cancer progression.
Four HDAC inhibitors have received FDA approval for cancer treatment. Vorinostat and romidepsin treat cutaneous T-cell lymphoma, a cancer of immune cells in the skin. Romidepsin and belinostat are approved for peripheral T-cell lymphoma. Panobinostat is used for multiple myeloma. All of these work by preventing HDACs from removing acetyl groups, keeping chromatin in a more open state and restoring expression of tumor-suppressing genes.
Research into bromodomain-targeting drugs is also active, since blocking the proteins that read acetyl marks can disrupt the gene programs that cancer cells depend on. The connection between metabolism, acetyl-CoA supply, and histone acetylation has also drawn interest in aging research, where calorie restriction’s effects on longevity appear to be partly mediated through reduced histone acetylation and increased autophagy.